Wire · operational-macro
What Eli Lilly's psychedelic investment could mean for the emerging field
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 September 2026 · Fusion42 review
Eli Lilly acquired AtaiBeckley for $2.8 billion to develop psychedelic medicines targeting treatment-resistant depression and alcohol use disorder, following a trend of large pharma companies investing heavily in psychedelics. The FDA is also supporting psychedelic drug development with faster review vouchers and updated clinical trial guidelines to address approval challenges.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
Psychedelic medicines are entering mainstream pharma with regulatory hurdles easing. If you build mental health treatments, prepare for faster FDA approvals and consider partnering with or competing against Big Pharma giants moving into your space.
◆ Coverage
1 source · 24 Sep 2026
◆ Related on Wire
◆ Topics